HOUSTON--(BUSINESS WIRE)--StemTroniX, Inc., a Texas corporation ("StemTroniX"), and Power3 Medical Products, Inc. (OTCBB:PWRM) announced today that a plenary address entitled “The Genesis of Prototype Biomarkers for Identification and Use of Stem Cells for Therapeutics of Alzheimer’s Disease” will be delivered by Ira L. Goldknopf, PhD, Power3’s President and Chief Scientific Officer, to the European Molecular Histopathology Symposium on The Impact of Personalized Medicine, April 29, 2010, in Chantilly, France, organized by Ventana Medical Systems, a member of the Roche Group.
